Ligand Pharmaceuticals (LGND) and Channel Therapeutics (CHRO) said Thursday they have agreed to merge Ligand's Pelthos Therapeutics and LNHC subsidiaries with Channel's CHRO Merger Sub in a deal worth $50 million.
Upon the expected summer 2025 completion of the transaction, the new company will operate under the name Pelthos Therapeutics and trade on the New York Stock Exchange under the ticker symbol "PTHS," the companies said.
The merger will be backed by $50 million in capital raised from a group of investors that includes Ligand and a group of investors led by Murchinson, the companies said.
The new company will initially focus on commercializing Pelthos' US Food and Drug Administration-approved Zelsuvmi topical gel for the treatment of Molluscum contagiosum, a contagious skin infection, the companies said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。